Lupin Ltd. said that its subsidiary Lupin Pharmaceuticals, Inc., had received approval from US FDA for Suprax (Cefixime) for Oral Suspension, 500 mg/5mL. The company expects to commence shipping the product in the near future.
Suprax (cefixime) for Oral Suspension is meant for the treatment of otitis media, acute exacerbation of chronic bronchitis, uncomplicated urinary tract infections, uncomplicated gonorrhea (cervical/urethral) and pharyngitis/tonsillitis.
The company said the approval would expand the company's range of Suprax dosage forms available to treat approved indications in appropriate patients.
Suprax is currently available as 100 mg/5ml and 200 mg/5ml suspensions, 400 mg tablets as well as chewable tablets 100 and 200 mg.
Commenting on the approval, Group President Ms. Vinita Gupta said, "We are happy to receive this approval. The new dosage form will add to our growing Suprax franchise and gives health care providers and patients a new formulation to treat the indicted infections. The approval of Suprax for Oral Suspension is one more example of our ongoing commitment to serving our customers and addressing their needs."
At the BSE, Lupin shares are currently trading at Rs.593.75, down 0.04 percent from the previous close.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.